Corvus Pharmaceuticals Inc (CRVS) - Total Liabilities
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has total liabilities worth $13.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Corvus Pharmaceuticals Inc (CRVS) investment intensity to see how much of total assets are deployed in long-term investments.
Corvus Pharmaceuticals Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CRVS total assets.
Corvus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STAAR Surgical Company
NASDAQ:STAA
|
USA | $109.81 Million |
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
USA | $795.73 Million |
|
Vitec Software Group AB (publ)
ST:VIT-B
|
Sweden | Skr6.50 Billion |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
India | Rs60.62 Billion |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
USA | $2.01 Billion |
|
Fengfan Power
SHG:601700
|
China | CN¥4.80 Billion |
|
Zhejiang Windey Co Ltd
SHE:300772
|
China | CN¥45.41 Billion |
|
Highpeak Energy Acquisition Corp
NASDAQ:HPK
|
USA | $1.62 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Corvus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Corvus Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corvus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual total liabilities of Corvus Pharmaceuticals Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.91 Million | -72.72% |
| 2024-12-31 | $36.34 Million | +429.03% |
| 2023-12-31 | $6.87 Million | -43.35% |
| 2022-12-31 | $12.12 Million | -1.37% |
| 2021-12-31 | $12.29 Million | -8.13% |
| 2020-12-31 | $13.38 Million | +6.75% |
| 2019-12-31 | $12.54 Million | +58.75% |
| 2018-12-31 | $7.90 Million | -20.56% |
| 2017-12-31 | $9.94 Million | +35.26% |
| 2016-12-31 | $7.35 Million | -94.33% |
| 2015-12-31 | $129.56 Million | +921.12% |
| 2014-12-31 | $12.69 Million | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more